Measure Information Form

Size: px
Start display at page:

Download "Measure Information Form"

Transcription

1 Release Ntes: Measure Infrmatin Frm Versin 2.0 **NQF-ENDORSED VOLUNTRY CONSENSUS STNDRDS FOR HOSPITL CRE** Measure Set: Heart Failure (HF) Set Measure ID#: Measure Infrmatin Frm Perfrmance Measure Name: CEI r R fr LVSD Descriptin: Heart failure patients with left ventricular systlic dysfunctin (LVSD) and withut bth angitensin cnverting enzyme inhibitr (CEI) and angitensin receptr blcker (R) cntraindicatins wh are prescribed an CEI r R at hspital discharge. Fr purpses f this measure, LVSD is defined as chart dcumentatin f a left ventricular ejectin fractin (LVEF) less than 40% r a narrative descriptin f left ventricular systlic (LVS) functin cnsistent with mderate r severe systlic dysfunctin. Ratinale: CEI therapy reduces mrtality and mrbidity in patients with heart failure and left ventricular systlic dysfunctin (The SOLVD Investigatrs, 1991 and CONSENSUS Trial Study Grup, 1987) and are effective in a wide range f patients (Masudi, 2004). Recent clinical trials have als established R therapy as an acceptable alternative t CEI, especially in patients wh are CEI intlerant (Granger, 2003 and Pfeffer, 2003). Natinal guidelines strngly recmmend CEIs fr patients hspitalized with heart failure (Hunt, 2005 and HFS, 1999). Guideline cmmittees have als supprted the inclusin f Rs in perfrmance measures fr heart failure (Executive Cuncil f the Heart Failure Sciety f merica, 2004). Despite these recmmendatins, CEIs and Rs remain underutilized in eligible lder patients hspitalized with heart failure (Jencks, 2000 and Masudi, 2004). Type f Measure: Prcess Imprvement Nted s: n increase in the rate Numeratr Statement: Heart failure patients wh are prescribed an CEI r R at hspital discharge Included Ppulatins: Nt pplicable Excluded Ppulatins: Nne Data Elements: CEI Prescribed at Discharge R Prescribed at Discharge -1

2 Denminatr Statement: Heart failure patients with LVSD and withut bth CEI and R cntraindicatins Included Ppulatins: Discharges with: n ICD-9-CM Principal Diagnsis Cde fr heart failure as defined in ppendix, Table 2.1 ND Chart dcumentatin f a LVEF less than 40% r a narrative descriptin f LVS functin cnsistent with mderate r severe systlic dysfunctin Excluded Ppulatins: Patients less than 18 years f age Patients transferred t anther acute care hspital r federal hspital Patients wh expired Patients wh left against medical advice Patients discharged t hspice Patients with cmfrt measures nly dcumented by a physician, nurse practitiner, r physician assistant Patients with OTH a ptential cntraindicatin/reasn fr nt prescribing an CEI at discharge ND a ptential cntraindicatin/reasn fr nt prescribing an R at discharge, as evidenced by ne r mre f the fllwing: CEI allergy ND R allergy Mderate r severe artic stensis Physician, nurse practitiner, r physician assistant dcumentatin f OTH a reasn fr nt prescribing an CEI at discharge ND a reasn fr nt prescribing an R at discharge Reasn dcumented by physician, nurse practitiner, r physician assistant fr nt prescribing an R at discharge ND an CEI allergy Reasn dcumented by physician, nurse practitiner, r physician assistant fr nt prescribing an CEI at discharge ND an R allergy Patients wh had a left ventricular assistive device (LVD) r heart transplant prcedure during hspital stay (ICD-9-CM prcedure cde fr LVD and heart transplant as defined in ppendix, Table 2.2) Data Elements: dmissin Date irthdate Cmfrt Measures Only Cntraindicatin t th CEI and R at Discharge Discharge Status ICD-9-CM Other Prcedure Cdes ICD-9-CM Principal Diagnsis Cde ICD-9-CM Principal Prcedure Cde LVSD -2

3 Risk djustment: N Data Cllectin pprach: Retrspective data surces fr required data elements include administrative data and medical recrds. Data ccuracy: Variatin may exist in the assignment f ICD-9-CM cdes; therefre, cding practices may require evaluatin t ensure cnsistency. Measure nalysis Suggestins: Nne Sampling: Yes, fr additinal infrmatin see the Sampling Sectin. Data Reprted s: ggregate rate generated frm cunt data reprted as a prprtin Selected References: nw RO, ennett S, Casey DE, Ganiats TG, Hlatky M, Knstam M, Lambrew CT, Nrmand ST, Piña IL, Radfrd MJ, Smith L, Stevensn L. CC/H Clinical Perfrmance Measures fr dults With Chrnic Heart Failure: a reprt f the merican Cllege f Cardilgy/merican Heart ssciatin Task Frce n Perfrmance Measures (Writing Cmmittee t Develp Heart Failure Clinical Perfrmance Measures). J m Cll Cardil 2005;46: vailable at and Effects f enalapril n mrtality in severe cngestive heart failure. Results f the Cperative Nrth Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Grup. N Engl J Med. 1987;316: Executive Cuncil f the Heart Failure Sciety f merica. Implicatins f recent clinical trials fr heart failure perfrmance measures. HFS Psitin Statement. J Card Fail. 2004;10:4-5. Granger C, McMurray JJ, Yusuf S et al. Effects f candesartan in patients with chrnic heart failure and reduced left-ventricular systlic functin intlerant t angitensincnverting-enzyme inhibitrs: the CHRM-lternative trial. Lancet. 2003;362: Heart Failure Sciety f merica (HFS) practice guidelines. HFS guidelines fr management f patients with heart failure caused by left ventricular systlic dysfunctinpharmaclgical appraches. J Card Fail Dec;5(4): Hunt S. CC/H 2005 guideline update fr the diagnsis and management f chrnic heart failure in the adult: a reprt f the merican Cllege f Cardilgy/merican Heart ssciatin Task Frce n Practice Guidelines (Writing Cmmittee t Update the 2001 Guidelines fr the Evaluatin and Management f Heart Failure). J m Cll Cardil 2005; 46(6):e1-82. Jencks SJ, Cuerdn T, urwen DR, Fleming, Huck PM, Kussmaul E, Nilasena DS, Ordin DL, rday DR. Quality f medical care delivered t Medicare beneficiaries: a prfile at state and natinal levels. JM. 2000;284: Masudi F, Rathre SS, Wang Y et al. Natinal patterns f use and effectiveness f angitensin-cnverting enzyme inhibitrs in lder patients with heart failure and left ventricular systlic dysfunctin. Circulatin. 2004;110:

4 Pfeffer M, McMurray JJ, Velazquez EJ et al. Valsartan, captpril, r bth in mycardial infarctin cmplicated by heart failure, left ventricular dysfunctin, r bth. N Engl J Med. 2003;349: The SOLVD Investigatrs. Effect f enalapril n survival in patients with reduced left ventricular ejectin fractins and cngestive heart failure. N Engl J Med, 325: ,

5 : CEI r R fr LVSD Numeratr: Heart failure patients wh are prescribed an CEI r R at hspital discharge. Denminatr: Heart failure patients with LVSD and withut bth CEI and R cntraindicatins. Start Variable Key: Patient ge ICD-9-CM Principal Diagnsis Cde Nt n Table 2.1 On Table 2.1 ICD-9-CM ll Invalid Principal r Other t least ne n Table 2.2 Prcedure Cdes ll Missing r Nne n Table 2.2 dmissin Date Valid irthdate Valid Patient ge(in years) = dmissin Date minus irthdate Nte: The algrithm t calculate age must use the mnth and day prtin f admissin date and birthdate t yield the mst accurate age. age is < 0 days (negative value) Patient ge age is > r = 0 days and < 18 years age is > r = 18 years Cmfrt Measures Only = Y (Initial ppulatin, cmmn t all measures in the HF set) = N H -5

6 H Discharge Status = 02, 07, 20, 41, 43, 50 r 51 = 01, 03, 04, 05, 06, 61, 62, 63, 64, 65, 66 LVSD = N = Y Missing r Invalid Measure Ppulatin Data Missing / Invalid Cntraindicatin t th CEI and R at Discharge =Y Nt In Measure Ppulatin Z =N Z CEI Prescribed at Discharge =Y =N, Missing/Invalid Missing / Invalid R Prescribed at Discharge = Y E In Numeratr Ppulatin = N C Missing r Invalid Numeratr Data Missing /Invalid CEI Prescribed at Discharge =N Measure Ppulatin DIn Z Stp -6

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): Angitensin

More information

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): EMeasure

More information

Measure Information Form

Measure Information Form Release Notes: Measure Information Form Version 2.0 **NQF-ENDORSED VOLUNTRY CONSENSUS STNDRDS FOR HOSPITL CRE** Measure Set: Heart Failure (HF) Set Measure ID#: Measure Information Form Performance Measure

More information

Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)

Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070) Crnary Artery Disease (CAD): Beta Blcker Therapy fr CAD Patients with Prir Mycardial Infarctin (MI) (NQF 0070) EMeasure Name Crnary Artery Disease EMeasure Id Pending (CAD): Beta Blcker Therapy fr CAD

More information

Measure Information Form

Measure Information Form **NQF-ENDORSED VOLUNTRY CONSENSUS STNDRDS FOR HOSPITL CRE** Measure Set: cute Myocardial Infarction (MI) Set Measure ID#: Measure Information Form Performance Measure Name: PCI Received Within 120 Minutes

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY

More information

High Performance Network Quality Criteria for Designation

High Performance Network Quality Criteria for Designation Selected quality measures include: Specialty Measure Descriptin Allergy / Immunlgy Asthma Drug Mgt Vaccine Pneumnia Vaccine High Perfrmance Netwrk Quality Criteria fr Designatin AvMed has selected certain

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY

More information

Weight Assessment and Counseling for Children and Adolescents (NQF 0024)

Weight Assessment and Counseling for Children and Adolescents (NQF 0024) Weight Assessment and Cunseling fr Children and Adlescents (NQF 0024) EMeasure Name Weight Assessment and EMeasure Id Pending Cunseling fr Children and Adlescents Versin Number 1 Set Id Pending Available

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...

More information

Measure Information Form

Measure Information Form Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Heart Failure (HF) Set Measure ID#: HF-1 Measure Information Form Performance

More information

Echocardiography Diagnostic Accuracy

Echocardiography Diagnostic Accuracy Echcardigraphy Diagnstic Accuracy Measure Descriptin: The prprtin f ptentially preventable and clinically imprtant inaccurate diagnses amng cngenital heart surgical patients. Numeratr Number f cngenital

More information

Diabetes: HbA1c Poor Control (NQF 0059)

Diabetes: HbA1c Poor Control (NQF 0059) Diabetes: HbA1c Pr Cntrl (NQF 0059) EMeasure Name Diabetes: HbA1c Pr Cntrl EMeasure Id Pending Versin Number 1 Set Id Pending Available Date N infrmatin Measurement January 1, 20xx thrugh Perid December

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface HTN-2 (NQF 0018): Cntrlling High Bld Pressure Measure Steward: NCQA CMS Web Interface V2.0 Page 1 f 18 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE SAMPLING INFORMATION... 4

More information

Childhood Immunization Status (NQF 0038)

Childhood Immunization Status (NQF 0038) Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December

More information

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Last Updated: Version 3.2 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Information Form Measure Set: Acute Myocardial Infarction (AMI) Set Measure ID#: Performance Measure Name:

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface IVD-2 (NQF 0068): Ischemic Vascular Disease (IVD): Use f Aspirin r Anther Measure Steward: NCQA CMS Web Interface V2.0 Page 1 f 20 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE

More information

Childhood Immunization Status (NQF 0038)

Childhood Immunization Status (NQF 0038) Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December

More information

Cardiac Rehabilitation Services

Cardiac Rehabilitation Services Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin

More information

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009 CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral

More information

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health

More information

LTCH QUALITY REPORTING PROGRAM

LTCH QUALITY REPORTING PROGRAM 4 LTCH QUALITY REPORTING PROGRAM GENERAL INFORMATION...3 LTCH FACILITY-LEVEL QUALITY MEASURE REPORT...5 LTCH PATIENT-LEVEL QUALITY MEASURE REPORT...18 LTCH REVIEW AND CORRECT REPORT...23 09/2018 v1.04

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface Diabetes Mellitus (DM) Cmpsite (All r Nthing Scring) DM-2 (NQF 0059): Diabetes: Hemglbin A1c (HbA1c) Pr Cntrl (>9%) DM-7 (NQF 0055): Diabetes: Eye Exam Measure Steward: NCQA Web Interface

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface PREV-12 (NQF 0418): Preventive Care and Screening: Screening fr Depressin and Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 23 06/25/ Cntents INTRODUCTION... 3 CMS WEB INTERFACE

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019

More information

MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache

MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache Measure Descriptin All patients diagnsed with migraine headache r cervicgenic headache wh had a headache management

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.1 Page 1 f 27 06/25/ Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-12 (NQF 0418): Preventive Care and Screening: Screening fr Depressin and Fllw-Up Measure Steward: CMS Web Interface V1.0 Page 1 f 22 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface Diabetes Mellitus (DM) Cmpsite (All r Nthing Scring) DM-2 (NQF 0059): Diabetes: Hemglbin A1c (HbA1c) Pr Cntrl (>9%) DM-7 (NQF Measure Steward: NCQA CMS Web Interface V2.1 Page 1 f 26

More information

Structured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information

Structured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.0 Page 1 f 27 11/13/2017 Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening and Fllw- Measure Steward: CMS Web Interface V1.0 Page 1 f 23 11/15/2016 Cntents INTRODUCTION... 3 WEB

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 24 06/25/ Cntents INTRODUCTION... 3 CMS WEB INTERFACE

More information

o Procedures performed o Diagnoses Identified o Certain devices/equipment/supplies acquired for patient

o Procedures performed o Diagnoses Identified o Certain devices/equipment/supplies acquired for patient Image Surce: https://s-media-cache-ak0.pinimg.cm/736x/7c/29/91/7c2991805f004e1ca05e42a79883f4a7.jpg 6/30/2017 Curse Objectives A Practical Guide t Cding fr Audilgists in 2017 Megan Keirans, AuD University

More information

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018) Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 27 06/25/ Cntents INTRODUCTION... 4 CMS WEB INTERFACE

More information

Obesity/Morbid Obesity/BMI

Obesity/Morbid Obesity/BMI Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin

More information

The data refer to persons aged between 15 and 54.

The data refer to persons aged between 15 and 54. Drug-related hspital stays in Australia 1993-2005 Prepared by Amanda Rxburgh and Luisa Degenhardt, Natinal Drug and Alchl Research Centre Funded by the Australian Gvernment Department f Health and Ageing

More information

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights. HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,

More information

Nonclinical factors associated with premature termination of adjuvant chemotherapy for stage I-III breast cancer

Nonclinical factors associated with premature termination of adjuvant chemotherapy for stage I-III breast cancer Nnclinical factrs assciated with premature terminatin f adjuvant chemtherapy fr stage I-III breast cancer Xia-Cheng Wu, Trevr Thmpsn, Meichin Hsieh, Meijia Zhu, Patricia Andrews, Michelle Lch, Timthy Styles,

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS Web Interface V1.1 Page 1 f 27 12/15/2016 Cntents INTRODUCTION... 4 WEB INTERFACE SAMPLING

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening Measure Steward: CMS CMS Web Interface V2.0 Page 1 f 23 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE

More information

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results

More information

UNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES.

UNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES. Initial privileges (initial appintment) Renewal f privileges (reappintment) Expansin f privileges (mdificatin) INSTRUCTIONS All new applicants must meet the fllwing requirements as apprved by the UNM SRMC

More information

Annual Principal Investigator Worksheet About Local Context

Annual Principal Investigator Worksheet About Local Context Cmpleting the NCI CIRB Annual Principal Investigatr Wrksheet Abut Lcal Cntext and the Study-Specific Wrksheet Abut Lcal Cntext at the University f Iwa All investigatrs cnducting research with the Natinal

More information

2018 CMS Web Interface

2018 CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS CMS

More information

APPENDIX A Certification of Advanced Disease:

APPENDIX A Certification of Advanced Disease: APPENDIX A Certificatin f Advanced Disease: Name: DOB: Member ID: Name f Palliative Care Prgram: A. General Criteria: Check each f the fllwing that apply (All needed fr eligibility). Patient wh is likely

More information

Nutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will:

Nutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will: Nutritin Care Prcess Mdel Tutrials Nutritin Care Prcess and Terminlgy Cmmittee Academy f Nutritin and Dietetics Nutritin Care Prcess Terminlgy 2015 Editin Nutritin Mnitring & Evaluatin: Overview & Definitin

More information

QUALITY AND SAFETY MEASURES UPDATE January 2016

QUALITY AND SAFETY MEASURES UPDATE January 2016 CLINICAL EFFECTIVENESS/SAFETY M CORE MEASURES 2015 See attached Results QUALITY AND SAFETY MEASURES UPDATE January 2016 Jint Cmmissin and CMS Cre Measure Dashbard updated with mst recent data available:

More information

Service Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin

Service Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin Service Change Prcess Gateway 1 High-level Prpsitin Innvatin prject name: Patient Self-Mnitring/Management f Warfarin NHS Bury Please describe the service change being prpsed. Please describe what service(s)

More information

COPD Outreach Program

COPD Outreach Program COPD Outreach Prgram Wendy Laframbise, Advanced Practice Nurse Certified Respiratry Educatr COPD Outreach Prgram March, 2015 Disclaimer: The Canadian Fundatin fr Healthcare Imprvement (CFHI), in partnership

More information

Meaningful Use Roadmap Stage Edition Eligible Hospitals

Meaningful Use Roadmap Stage Edition Eligible Hospitals Meaningful Use Radmap Stage 1-2011 Editin Eligible Hspitals CPSI is dedicated t making yur transitin t Meaningful Use as seamless as pssible. Therefre, we have cme up with a radmap t assist yu in implementing

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synpsis This Clinical Study Synpsis is prvided fr patients and healthcare prfessinals t increase the transparency f Bayer's clinical research. This dcument is nt intended t replace the advice

More information

ACRIN 6666 Screening Breast US Follow-up Assessment Form

ACRIN 6666 Screening Breast US Follow-up Assessment Form Screening Breast US Fllw-up Assessment Frm N. Instructins: The frm is cmpleted at 12, 24 and 36 mnths pst initial n study mammgraphy and ultrasund by the Radilgist r RA. Reprt all interim infrmatin related

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is

More information

o Prostanoids/prostacyclin therapies (oral and inhaled) o Inhaled agents: Ventavis, Tyvaso Page 1 of 5 Revised 02/17/17

o Prostanoids/prostacyclin therapies (oral and inhaled) o Inhaled agents: Ventavis, Tyvaso Page 1 of 5 Revised 02/17/17 Request fr Prir Authrizatin Pulmnary Arterial Hypertensin (PAH) Agents (Oral and Inhaled) Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 All requests fr Pulmnary Arterial

More information

A foot x-ray series is required only if there is pain in the midfoot zone and any one of the following:

A foot x-ray series is required only if there is pain in the midfoot zone and any one of the following: RADIOGRAPHY OF THE ANKLE AND FOOT (OTTAWA ANKLE RULES) Clinical Practice Guideline January 2007 This guideline has been adapted frm the Ottawa Ankle Rules develped by Dr. Ian Stiell et al. Dr. Stiell received

More information

Solid Organ Transplant Benefits to Change for Texas Medicaid

Solid Organ Transplant Benefits to Change for Texas Medicaid Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a

More information

Continuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP

Continuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit

More information

National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes

National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes Natinal Hspital Inpatient Quality Reprting Measures Specificatins Manual Release Ntes Fr Manual Versin: 5.6 Cmpleted: Nvember 28, 2018 Guidelines fr Using Release Ntes The Release Ntes prvides mdificatins

More information

2013 DATA COLLECTION GUIDE Summary Data Submission. Optimal Asthma Care. (07/01/2012 to 06/30/2013 Dates of Service)

2013 DATA COLLECTION GUIDE Summary Data Submission. Optimal Asthma Care. (07/01/2012 to 06/30/2013 Dates of Service) 2013 DATA COLLECTION GUIDE Summary Data Submissin Optimal Asthma Care (07/01/2012 t 06/30/2013 Dates f Service) Htline: 612-746-4522 E-mail: supprt@mncm.rg Data Prtal: https://data.mncm.rg/lgin MN Cmmunity

More information

Assessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams

Assessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.

More information

Podcast Transcript Title: Common Miscoding of LARC Services Impacting Revenue Speaker Name: Ann Finn Duration: 00:16:10

Podcast Transcript Title: Common Miscoding of LARC Services Impacting Revenue Speaker Name: Ann Finn Duration: 00:16:10 Pdcast Transcript Title: Cmmn Miscding f LARC Services Impacting Revenue Speaker Name: Ann Finn Duratin: 00:16:10 NCTCFP: Welcme t this pdcast spnsred by the Natinal Clinical Training Center fr Family

More information

Reliability and Validity Plan 2017

Reliability and Validity Plan 2017 Reliability and Validity Plan 2017 Frm CAEP The principles fr measures used in the CAEP accreditatin prcess include: (a) validity and reliability, (b) relevance, (c) verifiability, (d) representativeness,

More information

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this

More information

Commissioning Policy: South Warwickshire CCG (SWCCG)

Commissioning Policy: South Warwickshire CCG (SWCCG) Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding

More information

Use of sacubitril valsartan for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Shared Care Protocol

Use of sacubitril valsartan for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Shared Care Protocol Oxfrdshire Clinical Cmmissining Grup Use f sacubitril valsartan fr the treatment f symptmatic chrnic heart failure with reduced ejectin fractin. Shared Care Prtcl This prtcl prvides prescribing and mnitring

More information

Cardiac Rehabilitation in the Outpatient Setting Section 8.0 Therapy Subsection 8.03 Rehabilitation

Cardiac Rehabilitation in the Outpatient Setting Section 8.0 Therapy Subsection 8.03 Rehabilitation 8.03.08 Cardiac Rehabilitatin in the Outpatient Setting Sectin 8.0 Therapy Subsectin 8.03 Rehabilitatin Effective Date February 15, 2015 Original Plicy Date September 13, 1989 Next Review Date December

More information

HOSPITAL INPATIENT & EMERGENCY DEPARTMENT ANALYTICAL SYSTEM

HOSPITAL INPATIENT & EMERGENCY DEPARTMENT ANALYTICAL SYSTEM HOSPITAL INPATIENT & EMERGENCY DEPARTMENT ANALYTICAL SYSTEM healthdata.brhpc.rg The system prduces data reprts frm the fllwing mdules: Preventin Quality Indicatrs Acuity Stratificatin (Emergency Department)

More information

Cognitive enhancers for the treatment of Alzheimer s disease

Cognitive enhancers for the treatment of Alzheimer s disease Cmprehensive Research Plan: Cgnitive enhancers fr the treatment f Alzheimer s disease Pharmacepidemilgy Unit February 13 th, 2015 30 Bnd Street, Trnt ON, M5B 1W8 www.dprn.ca inf@dprn.ca 2 ODPRN Drug Class

More information

ACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals.

ACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals. 27 March 2014 Prfessr Debra Picne Chief Executive Officer Australian Cmmissin n Safety and Quality in Health Care c/ Ms Jennifer Hill, Senir Prject Officer Level 5, 255 Elizabeth Street SYDNEY NSW 2000

More information

NQF 0075 Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control

NQF 0075 Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control NQF 0075 Ischemic Vascular Disease (IVD): Cmplete Lipid Panel and LDL Cntrl Initial Patient Ppulatin: Numeratr(1): Numeratr(2): N Exclusin: Denminatr: D Exceptin: D Exclusin: Patients 18 years f age and

More information

To reduce harm to patients from Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in primary care

To reduce harm to patients from Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in primary care PPC CARE BUNDLE NSAIDs Aim T reduce harm t patients frm Nn-Steridal Anti-inflammatry Drugs (NSAIDs) in primary care Backgrund Nn-steridal anti-inflammatry drugs (NSAIDs) are the mst frequently prescribed

More information

OTHER AND UNSPECIFIED DISORDERS

OTHER AND UNSPECIFIED DISORDERS OPTUM COVERAGE DETERMINATION GUIDELINE OTHER AND UNSPECIFIED DISORDERS Guideline Number: BH727OUD_102017 Effective Date: Octber, 2017 Table f Cntents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...

More information

EMC believes the information in this publication is accurate as of its publication date. The information is subject to change without notice.

EMC believes the information in this publication is accurate as of its publication date. The information is subject to change without notice. EMC DATA PROTECTION ADVISOR (DPA) MIGRATION TECH NOTE With SQL as external database fr t 5.5.1 and later DPA versin 5.x releases t 6.0 SP1 and later ABSTRACT This Tech Nte prvides the steps t migrate frm

More information

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic

More information

Related Policies None

Related Policies None Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER

More information

Improving Surveillance and Monitoring of Self-harm in Irish Prisons

Improving Surveillance and Monitoring of Self-harm in Irish Prisons HSE Mental Health Divisin Stewart s Hspital, Palmerstwn, Dublin 20 Tel: 01 6201670 Email: inf@nsp.ie www.nsp.ie Imprving Surveillance and Mnitring f Self-harm in Irish Prisns Prject Scpe Dcument 8 th June

More information

National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes

National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes Natinal Hspital Inpatient Quality Reprting Measures Specificatins Manual Release Ntes Fr Manual Versin: 5.3 Cmpleted: June 15, 2017 Guidelines fr Using Release Ntes The Release Ntes prvides mdificatins

More information

MGPR Training Courses Guide

MGPR Training Courses Guide MGPR Training Curses Guide fiscal cde 92107050921 1. Descriptin The training prgram supprted by MGPR is prpsed by a grup f excellent mentrs/educatrs, accmplished in Pesticides Management and Analysis,

More information

Hearing Service Fees and Fee Codes Effective: January 01, 2019

Hearing Service Fees and Fee Codes Effective: January 01, 2019 Hearing Fees and Fee Cdes Effective: January 01, 2019 The WCB will fund the fllwing hearing services fr claims accepted fr traumatic and ccupatinal nise induced hearing: Fee cde 200 - Full audilgical assessment.

More information

Coding. Training Guide

Coding. Training Guide Cding (Specialty Hspital) Visin 4.3 (January 2013) Training Guide SurceMedical VisinSH Cding Learning Center f Excellence Last change made: January 2013 2013 Surce Medical Slutins, Inc. All Rights Reserved.

More information

Medicare Advantage 2019 Advance Notice Part 1 21 st Century Cures Act Methodological Changes

Medicare Advantage 2019 Advance Notice Part 1 21 st Century Cures Act Methodological Changes Medicare Advantage 2019 Advance Ntice Part 1 21 st Century Cures Act Methdlgical Changes Review f Relevant Prvisins with Expert Insight January 2018 PULSE8 is privileged t bring yu a summary f key Medicare

More information

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED

More information

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting

More information

Lyme Disease Surveillance in North Carolina

Lyme Disease Surveillance in North Carolina Lyme Disease Surveillance in Nrth Carlina 2008-2014 Carl Williams DVM Megan Sanza MPH Cmmunicable Disease Branch Divisin f Nrth Carlina Public Health Lyme Disease Surveillance in Nrth Carlina 2008-2014

More information

EUROPEAN MEDICINES AGENCY DECISION. of 14 October 2008

EUROPEAN MEDICINES AGENCY DECISION. of 14 October 2008 Eurpean Medicines Agency Dc. Ref. EMEA/522876/2008 P/84/2008 EUROPEAN MEDICINES AGENCY DECISION f 14 Octber 2008 n the applicatin fr agreement f a Paediatric Investigatin Plan fr valsartan (Divan) (EMEA-000005-PIP01-07)

More information

Indications and Limitations of Coverage and/or Medical back to top

Indications and Limitations of Coverage and/or Medical back to top Fr services perfrmed n r after 09/15/2009 Original Determinatin Ending Date Revisin Effective Date Revisin Ending Date Indicatins and Limitatins f Cverage and/r Medical Necessity Indicatins Medicare cverage

More information

Using Telin Mediplan to Support Patient s Medical Home

Using Telin Mediplan to Support Patient s Medical Home EMR TIP SHEET JANUARY 2017 Using Telin Mediplan t Supprt Patient s Medical Hme Cntents Intrductin... 3 Patient s Medical Hme... 3 Fundatin fr Success - Cmmitment t Standardizatin in the EMR... 4 Help Files...

More information

Affects a large segment of health care community Tied to health outcomes Addresses clinical conditions of high prevalence, high costs, high risks

Affects a large segment of health care community Tied to health outcomes Addresses clinical conditions of high prevalence, high costs, high risks Cding Change Applicatin Categry II CPT Cde(s) Perfrmance Measurement American Medical Assciatin, Current Prcedural Terminlgy (CPT ) Applicatin Submissin Requirements All CPT Cde Change applicatins are

More information

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder? updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health

More information

23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)

23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline) Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting

More information

HIP REPLACEMENT SURGERY (ARTHROPLASTY)

HIP REPLACEMENT SURGERY (ARTHROPLASTY) Prtcl: ORT015 Effective Date: June 1, 2017 HIP REPLACEMENT SURGERY (ARTHROPLASTY) Table f Cntents Page COMMERCIAL & MEDICAID COVERAGE RATIONALE... 1 MEDICARE COVERAGE RATIONALE... 3 U.S.FOOD AND DRUG ADMINISTRATION

More information

Michigan Primary Care Transformation Project Performance Incentive Technical Manual

Michigan Primary Care Transformation Project Performance Incentive Technical Manual Michigan Primary Care Transfrmatin Prject 2016 Perfrmance Incentive Technical Manual Fr Physician Organizatins, Physician Hspital Organizatins, Independent Practice Assciatins and Primary Care Practices

More information

Nutritional Intervention Effectiveness in Oncology Patients Receiving Active Anti-Cancer Treatment: A Systematic Review

Nutritional Intervention Effectiveness in Oncology Patients Receiving Active Anti-Cancer Treatment: A Systematic Review Nutritinal Interventin Effectiveness in Onclgy Patients Receiving Active Anti-Cancer Treatment: A Systematic Review Amanda Adams, RN, BSN, DNP-s FNP Track University at Buffal Schl f Nursing Disclser Learner

More information

Pediatric and adolescent preventive care and HEDIS *

Pediatric and adolescent preventive care and HEDIS * Pediatric and adlescent preventive care and HEDIS * * HEDIS is a registered trademark f the Natinal Cmmittee fr Quality Assurance (NCQA). UniCare Health Plan f West Virginia, Inc. Healthcare Effectiveness

More information

Pain Management Learning Plan

Pain Management Learning Plan Pain Management Learning Plan Overriding Gal T imprve the quality f patient care available fr patients living with chrnic pain. Learning Outcmes By the end f the implementatin, participants will be able

More information

Technical Specifications of Pediatric Ambulatory Care Sensitive Condition Hospitalizations

Technical Specifications of Pediatric Ambulatory Care Sensitive Condition Hospitalizations Technical Specificatins f Pediatric Ambulatry Care Sensitive Cnditin Hspitalizatins Surce: The Canadian Institute fr Health Infrmatin Database(s): Discharge Abstract Database (DAD) Level(s) f Care (facility

More information